IMV Inc IMVIF

RE:RE:RE:Timeline Chart - Jan.7 Presentation

[qwerty22]

I thought that was a great chat, Fred did well. Nice to have questioner whose both intelligent and positive.
Sound like dlbcl moves forward unchanged, no bridge chemo etc.
If the data supports that then that seems like pretty much the best possible outcome.
Head up on Merck's ongoing monotherapy trial would be welcome.

And some high promises for data delivery in the basket trial fairly soon, again super exciting.

We've been looking for them to move to the next stage of clinical development, sounds like it will happen this year.
Dare I say transformative year 2021?

Breakthorough wrote: Apart from DLBCL timeline, two important things in Q1: - They seem to have found a biomarker (not PD-L1, they said) in ovarian and will announce it. It should improve the results in the targeted population, of course. - Basket Trial interim results in more than 100 patients. Will have much more data in ovariam (with KTR and also wothout cyclophosphamide). I remember that unique patient in bladder cancer that had reached the first scan more than a year ago and had a 60% tumor reduction... Will see, and will see what's up with PD-L1 here... From this corporate presentation in January 7th: https://d1io3yog0oux5.cloudfront.net/_d915622917c42660070a2517ea402232/imvinc/db/854/8066/pdf/JAN072021_CORPORATE_PRESENTATION_POSTED+ONLINE.pdf